AJU Pharm Co., Ltd.
Quick facts
Marketed products
- B55R1 and B55R2 · Diabetes
B55R1 and B55R2 are inhibitors of the sodium-glucose cotransporter 2 (SGLT2). - B55R1 and placebo for B55R2 · Cardiovascular
B55R1 is a small molecule drug that works by inhibiting the activity of a specific enzyme. - OM-89 [Uro-Vaxom® Capsule]
Phase 3 pipeline
- A51R2
A51R2 is an investigational drug with unknown mechanism of action. - A51R3 · Diabetes
A51R3 is a small molecule that targets the SGLT2 receptor. - AJU-A51 · Diabetes
AJU-A51 is a small molecule drug that targets the SGLT2 receptor. - AJU-C52L, AJU-C52
AJU-C52L, AJU-C52 mechanism of action is not publicly available. - AJU-S56 5% · Diabetes
AJU-S56 5% is a small molecule drug that targets the SGLT2 receptor. - C52R1L, C52R1M
C52R1L and C52R1M are investigational drugs with unknown mechanisms of action. - Placebo Group(Vehicle)
A placebo (vehicle control) contains no active pharmaceutical ingredient and serves as an inert comparator in clinical trials.
Phase 1 pipeline
- A51R1 Tab. and A51R2 Tab.
- AJU-A51 Tab.
- AJU-C52H
- AJU-C52L
- AJU-R713
- C52R1H Tab. and C52R2 Tab.
- C52R1M Tab. and C52R2 Tab.
- R713R
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: